---
schema_version: "secwatch.filing_event.v1"
accession: "0000818479-25-000018"
form_type: "8-K"
ticker: "XRAY"
cik: "0000818479"
company_name: "DENTSPLY SIRONA Inc."
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:40:31.937450+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dentsply Sirona starts strategic review for Wellspect Healthcare unit

## Summary
- Wellspect provides bladder/bowel care products (LoFric, Navina); $2B TAM.
- Mid-to-high single-digit organic sales growth in 2023 and first 3Q of 2024.
- Goldman Sachs & Co. LLC (financial) and Wachtell Lipton (legal) retained as advisors.
- No deadline or assurance that a transaction will result from the review.
- Q4 & full-year 2024 results to be reported on February 27, 2025 as planned.

## SEC filing metadata
- accession: 0000818479-25-000018
- form_type: 8-K
- ticker: XRAY
- cik: 0000818479
- company_name: DENTSPLY SIRONA Inc.
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818479/000081847925000018/0000818479-25-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818479/000081847925000018/xray-20250211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000818479-25-000018
- JSON: https://secwatch.observer/filing/0000818479-25-000018.json
- Plain text: https://secwatch.observer/filing/0000818479-25-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.